Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program.
AAV
SEC-MALS
SV-AUC
cryo-EM
ddPCR
gene therapy
Journal
Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
medline:
24
4
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
To provide safe recombinant adeno-associated viruses (rAAV) to patients, scalable manufacturing processes are required. However, these processes may introduce impurities that impact the performance and quality of the final drug product. Empty rAAV capsids are product-related impurities. Regulatory guidance requires that accurate analytical methods be implemented early in product development to measure the level of empty capsids. A process confirmation vector, produced from 200 L production, was used to develop and optimize a size exclusion chromatography with UV and multiangle light scattering (SEC-MALS) method. Vector produced from a 500 L production was used to assess the full-to-empty ratio using the following analytical methods: sedimentation velocity analytical ultracentrifugation (SV-AUC), droplet digital PCR (ddPCR) with capsid enzyme-linked immunosorbent assay (ELISA), bulk absorbance at 260/280 nm, cryogenic electron microscopy, and SEC-MALS. This test article was used for a 30-day, non-Good Laboratory Practices animal study that assessed biodistribution of the product (STRX-330). SEC-MALS outperformed the other methods and correlated well with SV-AUC values of full-to-empty particles. In addition, SEC-MALS agreed with ddPCR and ELISA measurements for vector genomes/mL and capsid particles/mL, respectively. SEC-MALS was linear, accurate, and precise while achieving chromatography quality control (QC) recommendations. Compared to other stability-indicating assays, SEC-MALS performed similarly to ddPCR, capsid ELISA, and infectivity assays in accelerated stress studies. In response to alkaline, but not acidic stress, SEC-MALS indicated distinct changes in the DNA content of the monomer Adeno-associated viruses (AAV) peak for STRX-330, which was supported by ddPCR data. Conversely, acidic treatment resulted in more aggregated vector, but did not impact the DNA content. This work indicates that SEC-MALS is a valuable analytical tool in the analytical development and QC testing of AAV. In addition, this work suggests that SEC-MALS can provide fundamental understanding of AAV in response to environmental stress. This may impact steps of the manufacturing process to minimize conditions that reduce performance.
Identifiants
pubmed: 36927085
doi: 10.1089/hum.2022.218
pmc: PMC10125404
doi:
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-338Références
J Virol. 1971 Dec;8(6):860-63
pubmed: 5172922
Hum Gene Ther. 2015 May;26(5):257-65
pubmed: 25807962
Hum Gene Ther. 2022 Feb;33(3-4):202-212
pubmed: 34445880
Nat Commun. 2021 Mar 12;12(1):1642
pubmed: 33712599
Hum Gene Ther. 2004 Jul;15(7):709-15
pubmed: 15298029
Hum Gene Ther. 2021 Nov;32(21-22):1403-1416
pubmed: 34082578
Curr Gene Ther. 2013 Dec;13(6):434-52
pubmed: 24195602
JACC Clin Electrophysiol. 2022 Apr;8(4):533-553
pubmed: 35450611
Hum Gene Ther. 2011 May;22(5):595-604
pubmed: 21410419
J Struct Biol. 2020 Aug 1;211(2):107547
pubmed: 32522552
Pharmaceutics. 2021 Apr 20;13(4):
pubmed: 33923984
Mol Ther. 2022 Dec 7;30(12):3515-3541
pubmed: 36203359
Mol Ther Methods Clin Dev. 2021 Apr 09;21:548-558
pubmed: 33997103
Hum Gene Ther. 2019 Dec;30(12):1449-1460
pubmed: 31530236
Anal Chem. 2016 Jul 5;88(13):6718-25
pubmed: 27310298
J Virol. 1971 Nov;8(5):766-70
pubmed: 5132697
Sci Transl Med. 2013 Jul 17;5(194):194ra92
pubmed: 23863832
Virology. 2009 Mar 15;385(2):434-43
pubmed: 19144372
J Virol. 1978 Jan;25(1):331-8
pubmed: 621779
Mol Ther Methods Clin Dev. 2014;1(9):20139
pubmed: 25485285
Gene Ther. 2022 Dec;29(12):691-697
pubmed: 35046529
Hum Gene Ther Methods. 2015 Dec;26(6):228-42
pubmed: 26414997
Hum Gene Ther. 2010 Oct;21(10):1273-85
pubmed: 20486768
Hum Gene Ther. 2021 Jun;32(11-12):628-637
pubmed: 33081515
Hum Gene Ther. 2022 Nov;33(21-22):1142-1156
pubmed: 36082996
Methods Enzymol. 2012;507:229-54
pubmed: 22365777
J Am Chem Soc. 2014 May 21;136(20):7295-9
pubmed: 24787140
Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4812-E4821
pubmed: 28559317
Sci Rep. 2021 Feb 4;11(1):3012
pubmed: 33542328
Mol Ther Methods Clin Dev. 2021 Sep 01;23:254-262
pubmed: 34703846
Mol Ther. 2003 Jan;7(1):122-8
pubmed: 12573625
Virol J. 2005 May 06;2:43
pubmed: 15877812
Anal Biochem. 2007 Mar 1;362(1):16-37
pubmed: 17223062
Mol Ther Methods Clin Dev. 2021 Nov 29;24:40-47
pubmed: 34977271
J Arrhythm. 2016 Oct;32(5):398-403
pubmed: 27761164
Mol Ther. 2013 Sep;21(9):1648-50
pubmed: 24008618
Curr Gene Ther. 2005 Jun;5(3):299-310
pubmed: 15975007